![[Trade Alert] Happily Wrong](https://disruptivetr.com/wp-content/uploads/2020/06/PRVB-1.jpg)
[Trade Alert] Happily Wrong
Provention Bio (PRVB) successfully priced a $100 million offering. Here are all the details, along with three key data takeaways from the ADA meeting…
![[Trade Alert] Provention Bio (PRVB) Drops The F Bomb](https://disruptivetr.com/wp-content/uploads/2020/06/PRVB.F.Bomb_.jpg)
[Trade Alert] Provention Bio (PRVB) Drops The F Bomb
Provention Bio (PRVB) announced an offering after the bell yesterday on the heel’s of new data for its Type 1 Diabetes treatment. Here’s what I recommend…
PRVB: Major Risks Retired, Major Upside Ahead
Shares of Provention Bio (PRVB) have staged an impressive rally since announcing game-changing data on teplizumab for the treatment of patients at-risk of developing Type 1 Diabetes. But there’s plenty more upside ahead. Here’s why…
Don’t Go Chasing Bogeymen
With shares of Provention Bio (PRVB) selling off on no news, fight the tendency to go chasing bogeymen to justify selling. Instead, focus on insiders
Provention Bio (PRVB): Here We Go Again!
For the second time in less than four months, Provention announced a public offering. While I criticized the first attempt, here’s why I’m ecstatic this time around…
Provention Bio (PRVB): FDA Breakthrough Secured!
This morning, Provention Bio (PRVB) announced that the FDA granted Breakthrough Therapy Designation (BTD) to teplizumab (PRV-031). Here’s what to expect…